Olopatadine/mometasone
| Combination of | |
|---|---|
| Olopatadine | Selective histamine H1-receptor antagonist |
| Mometasone | Corticosteroid |
| Clinical data | |
| Trade names | Ryaltris |
| Other names | GSP 301 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Nasal spray |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2]
Common side effects include an unpleasant taste (dysgeusia).[1]
It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
